search
Back to results

The Effect of Anesthesia on Neurodevelopmental Outcome (NDO) (NDO)

Primary Purpose

Anesthesia; Adverse Effect, Congenital Heart Disease, Neurodevelopmental Disorders

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Isoflurane
Fentanyl (high dose)
Fentanyl (low dose)
Sponsored by
Stanford University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Anesthesia; Adverse Effect

Eligibility Criteria

1 Day - 36 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Neonates of at least 32 weeks of gestation, infants and children up to 2 years of age admitted to The Children's Hospital for treatment of cyanotic or non-cyanotic heart disease requiring surgical intervention.
  • Admitting diagnosis of cyanotic or non-cyanotic heart disease

Exclusion Criteria:

  • Neonates less than 32 weeks of gestational age, and children more than 2 years of age.
  • Any documented central nervous system malformations.
  • Any potential subject requiring unexpected postoperative Extracorporeal membrane oxygenation (ECMO) support

Sites / Locations

  • Stanford Childrens hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Volatile Anesthesia

Narcotic based anesthesia

Arm Description

In volatile anesthetic technique, maintenance of anesthesia will be standardized to the anesthesia will be standardized to the volatile anesthetic isoflurane. Rocuronium or pancuronium will be used for muscle relaxation. Additionally, narcotic fentanyl will be administered at no greater than 2 mcg/kg/hr (low dose). However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB.

In narcotic based anesthetic technique, no volatile anesthetics will be used past induction. Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose).

Outcomes

Primary Outcome Measures

Bayley III
Neurodevelopmental assessment scores are age dependent and based motor and behavioral abilities, often reported for normal or abnormal for age. Bayley Scales of Infant and Toddler Development, third edition, (Bayley III) is an instrument designed to measure the developmental functioning of infants and toddlers between the ages of 1 month and 42 months (age adjustments for prematurity are accommodated with the tool). It provides age specific composite scores for cognitive (91 items, score min 55 max 145), language (98 items, score min 47 max 153), and motor (138 items, score min 46 max 154) skills. For all scales, higher scores are better and lower scores indicate possible delay/deficit.
Electroencephalogram
Brain electrical activity: observation is for brain region specific abnormal or seizure activity. Number of participants with abnormal EEG are reported.

Secondary Outcome Measures

Choline
blood levels: time and patient dependent variation, observed patient related trends over time
Glutamate
blood levels:time and patient dependent variation, observed patient related trends over time
N-acetylaspartate (Naa)
blood levels:time and patient dependent variation, observed patient related trends over time
Lactate
blood levels:time and patient dependent variation, observed patient related trends over time

Full Information

First Posted
May 5, 2016
Last Updated
May 6, 2022
Sponsor
Stanford University
Collaborators
The Gerber Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT03882788
Brief Title
The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)
Acronym
NDO
Official Title
Anesthesia and the Developing Brain: a Comparison of Two Anesthetic Techniques
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
April 22, 2013 (Actual)
Primary Completion Date
November 19, 2020 (Actual)
Study Completion Date
November 19, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Stanford University
Collaborators
The Gerber Foundation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to assess whether the type of anesthesia, narcotic-based versus inhalational anesthesia administered during cardiopulmonary bypass (CPB) surgery contributes to the wide variation in neurologic recovery and developmental outcome after surgery in infants with congenital heart disease.
Detailed Description
All subjects will be consented prior to participation in this study and prior to randomization. All the subjects enrolled in the study will receive a preoperative assessment by one of the cardiac anesthesiologists and receive standardized induction with sevoflurane up to 2%, 2 mcg/kg of fentanyl and 1 mg/kg of rocuronium. The anesthetic maintenance will be determined using a computer- generated randomization table and assigning each patient to one of the two anesthetic regimens. Both of these anesthetic techniques are standard of care and are commonly used for these procedures. Anesthetic Technique: Volatile anesthetic: In volatile anesthetic technique, maintenance of anesthesia will be standardized to the volatile anesthetic isoflurane. Isoflurane will be used for the study since this is what is presently available on the CPB machines. Anesthesia at 1.0 minimum anesthetic concentration (MAC) indicates that at this concentration 50% of the patients will not move when surgically stimulated. Anesthesiologists commonly use about 1.2-1.4 MAC in neonates, since the MAC value in infants is higher than that of children and adults. Isoflurane will be delivered at 1.5-2.0%% as required for anesthetic management. Rocuronium or pancuronium will be used for muscle relaxation. Narcotic, fentanyl will be administered at no greater than 2 mcg/kg/hr. Narcotic-based anesthetic: In narcotic based anesthetic technique, no volatile anesthetics will be used except during induction. Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr. The anesthetic may be supplemented with dexmedetomidine 0.05 mcg/kg/hr but not to exceed 1.0 mcg/kg/hr. Narcotic-based anesthetic will be used by the cardiac anesthesia team and the CPB technician throughout the operative case. 5 mcg/kg/hr of fentanyl is felt to represent 0.6 MAC of anesthesia. Postoperative Sedative and Analgesic Care: As per institutional standard of care, postoperative sedation will consist of fentanyl infusions of 2-4 mcg/kg/hr for the first 48 hours postoperatively. A total of 9 Blood samples will be collected at different time points throughout the entire study for metabolomics determination (NAA/Cr and Chol/Cr) EEG monitoring will be done for baseline in the pre-operative period for 15-20 minutes, during surgery and post-operatively up to 48 hours and prior to discharge for 15-20 minutes. Neurological and behavioral testing including Bayley Exam III will be done at 18-48 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anesthesia; Adverse Effect, Congenital Heart Disease, Neurodevelopmental Disorders

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
EEG, metabolic/NMRS analysis and neurodevelopment outcome is blinded.
Allocation
Randomized
Enrollment
153 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Volatile Anesthesia
Arm Type
Active Comparator
Arm Description
In volatile anesthetic technique, maintenance of anesthesia will be standardized to the anesthesia will be standardized to the volatile anesthetic isoflurane. Rocuronium or pancuronium will be used for muscle relaxation. Additionally, narcotic fentanyl will be administered at no greater than 2 mcg/kg/hr (low dose). However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB.
Arm Title
Narcotic based anesthesia
Arm Type
Active Comparator
Arm Description
In narcotic based anesthetic technique, no volatile anesthetics will be used past induction. Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose).
Intervention Type
Drug
Intervention Name(s)
Isoflurane
Intervention Description
Isoflurane (volatile anesthesia) will be delivered at 1.5-2.0%% as required for anesthetic management.
Intervention Type
Drug
Intervention Name(s)
Fentanyl (high dose)
Intervention Description
Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.
Intervention Type
Drug
Intervention Name(s)
Fentanyl (low dose)
Intervention Description
Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 2 mcg/kg/hr.
Primary Outcome Measure Information:
Title
Bayley III
Description
Neurodevelopmental assessment scores are age dependent and based motor and behavioral abilities, often reported for normal or abnormal for age. Bayley Scales of Infant and Toddler Development, third edition, (Bayley III) is an instrument designed to measure the developmental functioning of infants and toddlers between the ages of 1 month and 42 months (age adjustments for prematurity are accommodated with the tool). It provides age specific composite scores for cognitive (91 items, score min 55 max 145), language (98 items, score min 47 max 153), and motor (138 items, score min 46 max 154) skills. For all scales, higher scores are better and lower scores indicate possible delay/deficit.
Time Frame
Assessed once between age 18 to 48 months (approximately 2 hours to assess), up to 48 months from study start
Title
Electroencephalogram
Description
Brain electrical activity: observation is for brain region specific abnormal or seizure activity. Number of participants with abnormal EEG are reported.
Time Frame
EEG taken immediately prior to surgery, during surgery, during cardiovascular intensive care unit (CVICU) stay (up to 48 hours after surgery), and immediately prior to discharge (between 5 to 20 minutes to assess EEG at each time point)
Secondary Outcome Measure Information:
Title
Choline
Description
blood levels: time and patient dependent variation, observed patient related trends over time
Time Frame
0-72 hours
Title
Glutamate
Description
blood levels:time and patient dependent variation, observed patient related trends over time
Time Frame
0-72 hours
Title
N-acetylaspartate (Naa)
Description
blood levels:time and patient dependent variation, observed patient related trends over time
Time Frame
0-72 hours
Title
Lactate
Description
blood levels:time and patient dependent variation, observed patient related trends over time
Time Frame
0-72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
36 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Neonates of at least 32 weeks of gestation, infants and children up to 2 years of age admitted to The Children's Hospital for treatment of cyanotic or non-cyanotic heart disease requiring surgical intervention. Admitting diagnosis of cyanotic or non-cyanotic heart disease Exclusion Criteria: Neonates less than 32 weeks of gestational age, and children more than 2 years of age. Any documented central nervous system malformations. Any potential subject requiring unexpected postoperative Extracorporeal membrane oxygenation (ECMO) support
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lisa W Faberowski, MD, MSc
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford Childrens hospital
City
Palo Alto
State/Province
California
ZIP/Postal Code
94305
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No IPD will be shared with other researchers

Learn more about this trial

The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)

We'll reach out to this number within 24 hrs